CN101479245B - 喹啉酮衍生物和其药物组合物 - Google Patents

喹啉酮衍生物和其药物组合物 Download PDF

Info

Publication number
CN101479245B
CN101479245B CN2007800244042A CN200780024404A CN101479245B CN 101479245 B CN101479245 B CN 101479245B CN 2007800244042 A CN2007800244042 A CN 2007800244042A CN 200780024404 A CN200780024404 A CN 200780024404A CN 101479245 B CN101479245 B CN 101479245B
Authority
CN
China
Prior art keywords
hydroxy
ylamino
indan
diethyl
quinolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800244042A
Other languages
English (en)
Chinese (zh)
Other versions
CN101479245A (zh
Inventor
O·洛泽
S·莫尼耶
J-L·雷伯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0613156A external-priority patent/GB0613156D0/en
Priority claimed from GB0613159A external-priority patent/GB0613159D0/en
Priority claimed from GB0613158A external-priority patent/GB0613158D0/en
Priority claimed from GB0613160A external-priority patent/GB0613160D0/en
Priority claimed from EP06117129A external-priority patent/EP1878722A1/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN101479245A publication Critical patent/CN101479245A/zh
Application granted granted Critical
Publication of CN101479245B publication Critical patent/CN101479245B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2007800244042A 2006-06-30 2007-07-02 喹啉酮衍生物和其药物组合物 Active CN101479245B (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB0613158.5 2006-06-30
GB0613156A GB0613156D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613159A GB0613159D0 (en) 2006-06-30 2006-06-30 Organic Compounds
GB0613159.3 2006-06-30
GB0613156.9 2006-06-30
GB0613158A GB0613158D0 (en) 2006-06-30 2006-06-30 Organic compounds
GB0613160.1 2006-06-30
GB0613160A GB0613160D0 (en) 2006-06-30 2006-06-30 Organic Compounds
EP06117129A EP1878722A1 (en) 2006-07-13 2006-07-13 Quinolinone derivatives and their pharmaceutical compositions
EP06117129.4 2006-07-13
PCT/EP2007/056632 WO2008000839A1 (en) 2006-06-30 2007-07-02 Quinolinone derivatives and their pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CN101479245A CN101479245A (zh) 2009-07-08
CN101479245B true CN101479245B (zh) 2013-05-22

Family

ID=38610531

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800244042A Active CN101479245B (zh) 2006-06-30 2007-07-02 喹啉酮衍生物和其药物组合物

Country Status (28)

Country Link
US (2) US8198450B2 (enExample)
EP (1) EP2044025B1 (enExample)
JP (1) JP5253392B2 (enExample)
KR (1) KR101402398B1 (enExample)
CN (1) CN101479245B (enExample)
AU (1) AU2007264946B2 (enExample)
BR (1) BRPI0713951B8 (enExample)
CA (1) CA2654801C (enExample)
CY (3) CY1113733T1 (enExample)
DK (1) DK2044025T3 (enExample)
ES (1) ES2396987T3 (enExample)
FI (2) FIC20200047I1 (enExample)
FR (2) FR20C1054I1 (enExample)
HR (1) HRP20121074T1 (enExample)
HU (2) HUS2000043I1 (enExample)
IL (1) IL195796A (enExample)
LT (2) LTC2044025I2 (enExample)
LU (2) LUC00185I2 (enExample)
MA (1) MA30540B1 (enExample)
MX (1) MX2008016542A (enExample)
MY (1) MY150468A (enExample)
NO (3) NO341709B1 (enExample)
NZ (1) NZ573292A (enExample)
PL (1) PL2044025T3 (enExample)
PT (1) PT2044025E (enExample)
SI (1) SI2044025T1 (enExample)
WO (1) WO2008000839A1 (enExample)
ZA (1) ZA200809948B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1860192A1 (en) 1996-09-17 2007-11-28 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
KR20120120453A (ko) 2007-09-05 2012-11-01 화이자 리미티드 Ｎ4-(2,2-다이플루오로-4ｈ-벤조〔1,4〕옥사진-3-온)-6-일〕-5-플루오로-ｎ2-〔3-(메틸아미노카보닐메틸렌옥시)페닐〕2,4-피리미딘다이아민의 지나포에이트 염
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
AU2014229361B2 (en) 2013-03-14 2016-08-04 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
EP3347345B1 (en) 2015-09-29 2019-07-31 Inke, S.A. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-quinolin-2-one l-tartrate
CN110724095B (zh) * 2019-09-12 2023-06-09 上海方予健康医药科技有限公司 一种茚达特罗乙酸盐的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1353692A (zh) * 1999-06-04 2002-06-12 诺瓦提斯公司 β2－肾上腺受体激动剂
WO2005110402A1 (en) * 2004-05-18 2005-11-24 Novartis Ag Combinations of glycopyrrolate and beta2 adrenoceptor agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05202301A (ja) * 1991-08-29 1993-08-10 Yamamoto Chem Inc ２−アニリノ−３−メチル−６−（Ｎ−ｎ−ブチル−Ｎ−シクロヘキシルアミノ）フルオランの結晶変態、その製造方法及びこの結晶変態を含有する記録材料
EP0688871A3 (en) * 1994-06-24 1998-07-08 Quest International B.V. Preparation of phytosphingosine derivative
FR2777279B1 (fr) * 1998-04-08 2004-08-13 Hoechst Marion Roussel Inc Nouvelles formes cristallines du 1s-[1alpha(2s*,3r*), 9 alpha] 6,10-dioxo-n-(2-ethoxy-5-oxo-tetrahydro-3-furanyl) -9[[(1-isoquinolyl)carbonyl]amino]octohydro-6h-pyridazino [1,2-a][1,2]diazepine-1-carboxamide
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0127430D0 (en) 2001-11-15 2002-01-09 Smithkline Beecham Corp Compounds
US7417051B2 (en) 2002-04-12 2008-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments comprising betamimetics and a novel anticholinergic
US7250426B2 (en) 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
TWI324150B (en) 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
PE20050211A1 (es) 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
CA2521271C (en) 2003-04-04 2011-01-04 Novartis Ag Quinoline-2-one-derivatives for the treatment of airways diseases
JP2005343889A (ja) 2004-05-06 2005-12-15 Taisho Pharmaceut Co Ltd イミダゾピリジン誘導体
GB0413960D0 (en) 2004-06-22 2004-07-28 Novartis Ag Organic compounds
DK1869049T3 (da) 2005-03-21 2009-05-18 Lilly Co Eli Imidazopyridazinforbindelser
GB0511065D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1353692A (zh) * 1999-06-04 2002-06-12 诺瓦提斯公司 β2－肾上腺受体激动剂
WO2005110402A1 (en) * 2004-05-18 2005-11-24 Novartis Ag Combinations of glycopyrrolate and beta2 adrenoceptor agonists

Also Published As

Publication number Publication date
MA30540B1 (fr) 2009-06-01
AU2007264946A1 (en) 2008-01-03
ES2396987T3 (es) 2013-03-01
HUS2000043I1 (hu) 2020-12-28
LUC00188I2 (enExample) 2024-07-01
CA2654801A1 (en) 2008-01-03
PL2044025T3 (pl) 2013-02-28
ZA200809948B (en) 2009-05-25
NO2020041I1 (no) 2020-11-23
NO2020044I1 (no) 2020-12-07
HUS2000053I1 (hu) 2020-12-28
BRPI0713951A2 (pt) 2012-12-04
AU2007264946B2 (en) 2011-01-20
FR20C1063I1 (fr) 2021-01-22
BRPI0713951B8 (pt) 2021-05-25
CA2654801C (en) 2014-08-19
KR101402398B1 (ko) 2014-06-03
JP5253392B2 (ja) 2013-07-31
FIC20200047I1 (fi) 2020-11-27
FR20C1054I1 (fr) 2020-12-25
EP2044025A1 (en) 2009-04-08
NZ573292A (en) 2011-03-31
KR20090023651A (ko) 2009-03-05
CY1113733T1 (el) 2016-06-22
CY2020041I1 (el) 2021-03-12
US20090325912A1 (en) 2009-12-31
FIC20200050I1 (fi) 2020-12-16
LTPA2020535I1 (lt) 2020-12-28
CN101479245A (zh) 2009-07-08
HK1127597A1 (en) 2009-10-02
HRP20121074T1 (hr) 2013-01-31
JP2009541455A (ja) 2009-11-26
US8198450B2 (en) 2012-06-12
CY2020038I2 (el) 2021-03-12
SI2044025T1 (sl) 2013-01-31
IL195796A0 (en) 2009-09-01
BRPI0713951B1 (pt) 2019-08-13
LUC00185I2 (enExample) 2024-07-01
CY2020041I2 (el) 2021-03-12
DK2044025T3 (da) 2013-01-14
US20120316142A1 (en) 2012-12-13
WO2008000839A1 (en) 2008-01-03
CY2020038I1 (el) 2021-03-12
IL195796A (en) 2016-03-31
MY150468A (en) 2014-01-30
MX2008016542A (es) 2009-01-19
PT2044025E (pt) 2012-12-17
NO20090312L (no) 2009-01-28
LTPA2020538I1 (lt) 2021-01-11
NO341709B1 (no) 2018-01-02
LTC2044025I2 (lt) 2022-10-10
EP2044025B1 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
AU2004226824B2 (en) Quinoline-2-one-derivatives for the treatment of airways diseases
CN101479245B (zh) 喹啉酮衍生物和其药物组合物
JP2010501631A (ja) β−アドレナリン受容体アゴニストとしてのインダン−２−イルアミノ−ヒドロキシエチル−キノリン・マレイン酸塩誘導体の多形結晶形態
JP2006501207A (ja) 有機化合物
JP2010501611A (ja) （ｒ）−３−（２−ヒドロキシ−２，２−ジフェニル−アセトキシ）−１−（イソキサゾール−３−イルカルバモイル−メチル）−１−アゾニア−ビシクロ−［２．２．２］オクタン・臭化物塩
RU2449991C2 (ru) Производные хинолинона и содержащие их фармацевтические композиции
EP1878722A1 (en) Quinolinone derivatives and their pharmaceutical compositions
HK1127597B (en) Quinolinone derivatives and their pharmaceutical compositions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG